Printer Friendly

GENova files patent for new breast cancer treatment.

GENova Biotherapeutics, Inc., (New York, NY), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, has filed a patent for a potential blockbuster drug target that combats breast cancer. The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.

This novel approach--using proteins to stop cancer--is based on recent discoveries that indicate that most tumors are derived from a cancer stem cell. The technology behind Tetanolic acid involved identifying specific characteristics of these cancer stem cells and then tailoring a lipid (Tetanolic acid) that can identify these characteristics and then attack the malignant cells whilst leaving healthy cells intact. This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, with no side effects, and no harm to surrounding healthy tissues.

"This target has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy," says Aaron Whiteman for GENova.

Worldwide, breast cancer is the fifth most common cause of cancer death, and is the most common cancer (and cause of cancer death) in women. The demand for new and better treatments for the disease is as urgent as ever.

Whiteman explains GENova's novel approach: "If you compared this disease to a tree, so far, treatments have only treated the crown of the tree - its branches and leaves, and even tried to hit the stem, but no treatment has penetrated its roots. Now that we can identify cancer stem cells, we can remove the root at its formation, and therefore eliminate all sources of life to the tumor. That is the potential behind Tetonolic acid."

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen, Myriad Genetics, Medarex, and Biogen Idec.

GENova Biotherapeutics, Inc.

1-866-797-8703

www.genovabio.com
COPYRIGHT 2009 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:BIOTECH Patent News
Date:Aug 1, 2009
Words:359
Previous Article:Isis receives notice of allowance that expands the scope of key RNA therapeutic patents for single-stranded RNAi technology.
Next Article:Universita Degli Studi Di Milano obtains United States patent.
Topics:


Related Articles
Oxford GlycoSciences files patent application for breast cancer proteins and genes.
Genzyme Molecular Oncology receives breast and ovarian cancer patent.
Bionomics files further patents for BNO69 cancer target.
Introgen announces additional broad patent in china for p53 combination therapies.
GENova Biotherapeutics signs collaboration agreement with Bridge Bioresearch.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters